Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Pembrolizumab + Lenvatinib for Ovarian Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial tests the combination of pembrolizumab and lenvatinib in patients with clear cell ovarian cancer that has returned or not responded to treatment. Pembrolizumab boosts the immune system to fight cancer, and lenvatinib blocks proteins that help cancer grow. These medications have been used together for various cancers, showing promising results.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service